KH6.F NewAmsterdam Pharma Company N.V.

Healthcare Biotechnology Frankfurt Exchange
17.75 EUR
Close of Nov 12, 2026
16.05 35.00
Market cap
EUR 2.13B
P/E
-
P/B
3.55x
ROE
-27.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KH6.F undervalued?

Graham number

The Graham number of NewAmsterdam Pharma Company N.V. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NewAmsterdam Pharma Company N.V. fundamental analysis

No fundamental analysis for NewAmsterdam Pharma Company N.V. yet.

NewAmsterdam Pharma Company N.V. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial fo…

Full company profile